Andernach, February 20, 2019<\/p>\n\n\n\n
EsoCap AG and LTS Lohmann Therapy-Systeme AG announced the start of cooperation on industrial development of a unique drug delivery technology for diseases of the upper gastrointestinal tract. This collaboration leverages the collective expertise of a strong partner in the thin film industry with a highly innovative application technology.<\/p>\n\n\n\n
\u201cWe are particularly pleased to be partnering with LTS, a global leader in the development and manufacture of film technologies for the pharmaceutical industry\u201d, said Isabelle Racamier, EsoCap CEO. \u201cWe are committed to working closely with LTS to enter rapidly into a clinical trial in patients suffering from eosinophilic esophagitis. EsoCap technology may be beneficial in at least six indications affecting 370 million patients.\u201d<\/p>\n\n\n\n
Under the terms of this cooperation, LTS is working on implementation of its thin film know-how as applied to EsoCap\u2019s unique drug delivery technology for diseases of the upper gastrointestinal tract.<\/p>\n\n\n\n
\u201cAs a company committed to delivering pharmaceutical solutions based on our thin film technology, we are greatly interested in expanding our technology\u2019s fields of application.\u201d, said Dr. Hanshermann Franke, Senior VP Research and Development at LTS. \u201cWe are thrilled by EsoCap\u2019s highly innovative approach in the area of drug delivery to the upper gastrointestinal tract.\u201d<\/p>\n\n\n\n
About LTS Lohmann Therapie-Systeme AG<\/strong> For more information, please visit www.ltslohmann.de.<\/p>\n\n\n\n About EsoCap AG<\/strong>
LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems, such as Transdermal Patches (\u201cTTS\u201d) and Oral Thin Films (\u201cOTF\u201d) for the pharmaceutical industry. LTS\u00b4s commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. LTS\u2019s innovation pipeline contains both partner-funded and proprietary, LTS-funded projects. LTS maintains its leading position through continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches for transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, New Jersey, USA, with a representation in Shanghai, China.<\/p>\n\n\n\n
EsoCap AG is a Swiss privately funded company based in Basel, Switzerland.
EsoCap\u2019s vision is to improve the lives of patients with serious diseases through development of a unique topical drug delivery platform for diseases of the upper gastrointestinal tract.
Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short transit times, with less than two seconds from the mouth to the stomach.
EsoCap owns a unique drug delivery platform, allowing the topical application of drug substances for local treatment of diseases of the upper gastrointestinal tract.<\/p>\n\n\n\n